Zoledronic acid, which is an anti-osteoporotic drug assigned to a class of pharmaceuticals called bisphosphonates, effectivelyinhibitstheenzymefarnesyldiphosphatesynthase intheHMG-CoAreductasepathwaywhichcanleadtosignificant reduction in the osteoclast-like cell formation [4, 5] . Therefore, this effect of zoledronic acid might contribute as oneofthemajormechanismsforreducedbonedestructionin WDLS.
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DearEditor,
Well-differentiated liposarcoma (WDLS), which is the mostcommonsubtypeofliposarcoma,canproducemetastases with bone destruction [1] . I read with great interest the articlebyMystakidouandcolleagues [2] .IwouldliketocompletethediscussionofMystakidouandcolleaguesbyintroducing a major route by which zoledronic acid could influence bonemetastasesofliposarcoma.
Bone resorption in metastasis of WDLS is related to the increasedratesoftumoralcellsassociatedwithosteoclastactivity. Recent histopathologic findings revealed areas with sheets of osteoclast-type giant cells in the metastatic foci of WDLS [1] . Fusion of the cell membrane of preosteoclasts is anessentialinitialstepinosteoclastmaturation.Cholesterol in the membranes of preosteoclasts has a major role in the osteoclast-like cell formation via cellular membrane fusion
